Literature DB >> 2901886

In vivo assay for neuroleptic receptor binding in the striatum. Positron tomography in humans.

H Cambon1, J C Baron, J P Boulenger, C Loc'h, E Zarifian, B Maziere.   

Abstract

Using PET, we investigated the potency in six patients of therapeutic doses of neuroleptic drugs for preventing specific binding of trace doses of intravenously administered 76Br-labelled bromospiperone to corpus striatum in vivo. Measured receptor occupancy showed a clear-cut dose-dependent saturation curve with increasing daily oral dose of neuroleptics, indicating the validity and reliability of the method when used as an in vivo radioreceptor assay. Following drug withdrawal in eight patients, recovery to normal or supranormal receptor availability occurred in a matter of days. The results demonstrate an approach that may help resolve controversies about, and design better strategies for, neuroleptic treatment schedules.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2901886     DOI: 10.1192/bjp.151.6.824

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  11 in total

1.  In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia.

Authors:  J L Martinot; M L Paillère-Martinot; M F Poirier; M H Dao-Castellana; C Loc'h; B Mazière
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

2.  The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography.

Authors:  C J Bench; A A Lammertsma; P M Grasby; R J Dolan; S J Warrington; M Boyce; K P Gunn; L Y Brannick; R S Frackowiak
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

3.  Rebound insomnia after abrupt clozapine withdrawal.

Authors:  J Staedt; G Stoppe; G Hajak; E Ruther
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1996       Impact factor: 5.270

4.  Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels.

Authors:  J C Baron; J L Martinot; H Cambon; J P Boulenger; M F Poirier; V Caillard; J Blin; J D Huret; C Loc'h; B Maziere
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

5.  Striatal dopamine D2 receptors in tardive dyskinesia: PET study.

Authors:  J Blin; J C Baron; H Cambon; A M Bonnet; B Dubois; C Loc'h; B Mazière; Y Agid
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-11       Impact factor: 10.154

6.  Dose dependent occupancy of central dopamine D2 receptors by the novel neuroleptic CP-88,059-01: a study using positron emission tomography and 11C-raclopride.

Authors:  C J Bench; A A Lammertsma; R J Dolan; P M Grasby; S J Warrington; K Gunn; M Cuddigan; D J Turton; S Osman; R S Frackowiak
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 7.  Where have we got to with neuroreceptor mapping of the human brain?

Authors:  B Mazière; M Mazière
Journal:  Eur J Nucl Med       Date:  1990

8.  Differences between antipsychotic drugs in persistence of brain levels and behavioral effects.

Authors:  B M Cohen; T Tsuneizumi; R J Baldessarini; A Campbell; S M Babb
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

9.  A cross-validation study on the relationship between central D2 receptor occupancy and serum perphenazine concentration.

Authors:  Mirjam Talvik; Anna-Lena Nordström; Niels-Erik Larsen; Aurelija Jucaite; Simon Cervenka; Christer Halldin; Lars Farde
Journal:  Psychopharmacology (Berl)       Date:  2004-03-06       Impact factor: 4.530

10.  Two cases of long term dopamine D2 receptor blockade after depot neuroleptics.

Authors:  C Harasko-van der Meer; T Brücke; S Wenger; P Fischer; L Deecke; I Podreka
Journal:  J Neural Transm Gen Sect       Date:  1993
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.